v3.26.1
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
Total
Preferred Stock
Series B Preferred Stock
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2024   5 85,215    
Beginning balance at Dec. 31, 2024 $ 50,119 $ 0 $ 85 $ 174,779 $ (124,745)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation 1,599     1,599  
Exercise of warrants (in shares)     50    
Exercise of stock options (in shares)     489    
Exercise of stock options 316   $ 1 315  
Retirement of common shares (in shares)     (106)    
Net loss (23,123)       (23,123)
Ending balance (in shares) at Mar. 31, 2025   5 85,648    
Ending balance at Mar. 31, 2025 28,911 $ 0 $ 86 176,693 (147,868)
Beginning balance (in shares) at Dec. 31, 2024   5 85,215    
Beginning balance at Dec. 31, 2024 50,119 $ 0 $ 85 174,779 (124,745)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (36,402)        
Ending balance (in shares) at Jun. 30, 2025   5 98,510    
Ending balance at Jun. 30, 2025 95,565 $ 0 $ 99 256,613 (161,147)
Beginning balance (in shares) at Mar. 31, 2025   5 85,648    
Beginning balance at Mar. 31, 2025 28,911 $ 0 $ 86 176,693 (147,868)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation 2,035     2,035  
Exercise of warrants (in shares)     200    
Exercise of warrants 300     300  
Exercise of stock options (in shares)     907    
Exercise of stock options 994   $ 1 993  
Public offerings, net of issuance costs (in shares)     11,173    
Public offerings, net of issuance costs 71,768   $ 11 71,757  
Conversion of convertible notes into common stock (in shares)     704    
Conversion of convertible notes into common stock 4,836   $ 1 4,835  
Acquisition adjustment (in shares)     (122)    
Net loss (13,279)       (13,279)
Ending balance (in shares) at Jun. 30, 2025   5 98,510    
Ending balance at Jun. 30, 2025 95,565 $ 0 $ 99 256,613 (161,147)
Beginning balance (in shares) at Dec. 31, 2025   5 120,070    
Beginning balance at Dec. 31, 2025 245,832 $ 0 $ 120 442,532 (196,820)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation 4,817     4,817  
Vesting of restricted stock units (in shares)     81    
Vesting of restricted stock units (270)     (270)  
Exercise of warrants (in shares)     372    
Exercise of warrants 2,783   $ 1 2,782  
Exercise of stock options (in shares)     362    
Exercise of stock options 269     269  
Conversion of convertible notes into common stock (in shares)     420    
Conversion of convertible notes into common stock 5,059     5,059  
Acquisition of Apium/Quaze (in shares)     536    
Acquisition of Apium/Quaze 6,802   $ 1 6,801  
Net loss (26,553)       (26,553)
Ending balance (in shares) at Mar. 31, 2026   5 121,841    
Ending balance at Mar. 31, 2026 238,739 $ 0 $ 122 461,990 (223,373)
Beginning balance (in shares) at Dec. 31, 2025   5 120,070    
Beginning balance at Dec. 31, 2025 $ 245,832 $ 0 $ 120 442,532 (196,820)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of warrants (in shares) 572        
Exercise of stock options (in shares) 738        
Public offerings, net of issuance costs (in shares) 27,527        
Conversion of convertible notes into common stock (in shares) 420        
Net loss $ (61,812)        
Ending balance (in shares) at Jun. 30, 2026   5 152,691    
Ending balance at Jun. 30, 2026 471,175 $ 0 $ 153 729,654 (258,632)
Beginning balance (in shares) at Mar. 31, 2026   5 121,841    
Beginning balance at Mar. 31, 2026 238,739 $ 0 $ 122 461,990 (223,373)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Stock-based compensation 5,042     5,042  
Vesting of restricted stock units (in shares)     824    
Vesting of restricted stock units (822)   $ 1 (823)  
Exercise of warrants (in shares)     200    
Exercise of warrants 1,525     1,525  
Exercise of stock options (in shares)     376    
Exercise of stock options 268     268  
Public offerings, net of issuance costs (in shares)     27,527    
Public offerings, net of issuance costs 245,238   $ 28 245,210  
Acquisition of Apium/Quaze (in shares)     1,923    
Acquisition of Apium/Quaze 16,444   $ 2 16,442  
Net loss (35,259)       (35,259)
Ending balance (in shares) at Jun. 30, 2026   5 152,691    
Ending balance at Jun. 30, 2026 $ 471,175 $ 0 $ 153 $ 729,654 $ (258,632)